CVSA

Analyst Note: Covista (CVSA)

Date: 2026-06-20 Current Price: $119.07

1. Structural Readiness

• Conservative Entry: Not yet triggered. A conservative entry requires a confirmed breakout above the coil resistance level.
• Breakout Level: Not yet established.
• Current Price: $119.07.
• Extension: Not applicable (price has not yet broken out to measure extension).
• ATR Context: Current ATR is 3.8% (productive). This sits within the historical "high" sweet spot (4–6% is ideal, 3.8% is close to the lower bound of the productive range), suggesting manageable volatility for position sizing once a breakout occurs.

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Macro Thesis Status: NONE NAMED

As of 2026-06-20, there is no named secular macro thesis attached to this specific setup. The investment case is strictly tactical, driven by the quality of the technical setup (the forming coil) and the immediate fundamental strength recorded in the most recent earnings and filings. We are judging this name on its setup quality and business fundamentals, not on an invented macro narrative.

3. Business Overview

Company: Covista (CVSA) Industry: Healthcare Education / Higher Education Business Model: Covista operates as a leading healthcare educator in the U.S., generating revenue through tuition and fees for students across its portfolio of institutions. Revenue is recognized when control of services is transferred to students.

Key Business Components (as of 2026-06-20):

• Portfolio: The system includes Chamberlain University, Walden University, American University of the Caribbean School of Medicine (AUC), Ross University School of Medicine (RUSM), and Ross University School of Veterinary Medicine (RUSVM).
• Market Position: Chamberlain holds the largest BSN, MSN, FNP, and DNP programs in the U.S. based on total enrollments (Fall 2024 data).
• Operational Momentum: Management reported that Chamberlain returned to positive total enrollment growth ahead of expectations. Operating changes committed to previously are "in fact, working."
• Capacity Expansion: Six new campuses are in active development, with the first beginning teaching in September 2026. Two additional campuses have received full regulatory approval since the prior Investor Day.
• Employer Integration: The company is increasingly connecting its capacity to produce health care workers directly to employers through programs that fund education and create hiring pathways.
• Financial Guidance: In the Q1 2026 earnings transcript (May 7, 2026), management raised Adjusted EPS guidance to a range of $7.95 to $8.15, up from the prior range of $7.80 to $8.00.
• Capital Allocation: On December 15, 2025, the Board authorized a sixteenth share repurchase program allowing for up to $750.0 million of common stock to be repurchased through December 15, 2028.
• Regulatory & Compliance: The company maintains two surety-backed letters of credit totaling $179.0 million (10% of consolidated Title IV funds) at the request of the Department of Education (ED). Walden University has received a provisional PPA through June 30, 2025, with recertification submitted.

4. Archetype and Conviction

Archetype: Quality Compounder Fit Rationale: The name fits the "Quality Compounder" archetype due to its dominant market position in healthcare education, consistent enrollment growth (Chamberlain returning to positive growth), and strong operational execution. The business model benefits from a structural supply/demand imbalance in the healthcare sector, with roughly 700,000 health care jobs posted every month against only 306,000 unemployed health care workers.

Conviction Stack:

• Thesis Strength: Moderate (Tactical/Setup-led, no macro thesis).
• Evidence Quality: High. Recent earnings (May 2026) show raised EPS guidance and confirmed enrollment growth.
• Structural Quality: Strong. The company is expanding capacity (6 new campuses) and has deep clinical relationships.
• Setup Readiness: Partial. The "forming" coil indicates the market is digesting the positive news, but a breakout is required to confirm the trend continuation.
• Rerating Potential: Dependent on the successful execution of the new campus openings and the continued realization of the raised EPS guidance.

Valuation Context: While specific P/E multiples are not provided in the evidence block, the raised EPS guidance ($7.95–$8.15) combined with a price of $119.07 implies a forward P/E ratio in the range of approximately 14.7x to 15.0x. This valuation appears reasonable for a company with double-digit growth expectations and a dominant market position, provided the guidance is met.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Continued Enrollment Growth: Confirmation that Q4 2026 maintains the momentum of Q3 2026 as management expects ("Q4 to look like Q3").
• Successful Campus Launches: The September 2026 start of the first new campus without regulatory delays.

What Would Invalidate the Case:

• Regulatory Setbacks: Any adverse action from the Department of Education regarding the Borrower Defense to Repayment (BDR) applications or the loss of PPA status for Walden University.
• Guidance Miss: Failure to meet the raised EPS guidance of $7.95–$8.15.

Gaps in Evidence Base:

• Specific Breakout Level: The exact price level for the coil resistance (breakout trigger) is not provided in the data.
• Debt Covenants: While Amendment No. 5 to the Credit Agreement is mentioned, specific covenant terms or leverage ratios post-amendment are not detailed.
• Q2 2026 Results: The evidence block contains Q1 2026 data (ended March 31, 2026). Q2 2026 results are not yet available as of the event date (June 20, 2026), creating a gap in the most recent quarterly performance data.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Raised EPS guidance to $7.95-$8.15; Chamberlain returned to positive enrollment growth ahead of expectations; 6 new campuses in active development with first opening September 2026; structural labor shortage (700k jobs vs 306k unemployed). Key risks: Regulatory uncertainty regarding BDR applications and PPA recertification; potential delay in new campus openings; price failure to break out of the forming coil structure. Sizing hint: Position size should be calibrated to the 3.8% ATR, anticipating a potential wait for the breakout confirmation before adding full size. Expected path: Management expects Q4 to mirror Q3 momentum; new campuses begin teaching in September; share repurchase program continues through 2028. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.